share_log

B of A Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $37

Benzinga ·  Jan 2 11:07

B of A Securities analyst Jason Gerberry maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $29 to $37.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment